Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Concurrent RB1 loss and BRCA -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma

medRxiv(2023)10.1101/2023.11.09.23298321Source: DataRank Database

Concurrent RB1 loss and BRCA -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma is a research paper published in medRxiv (2023). On theSindex it has a DataRank of 0.269. It has been cited 5 times.

N/A

0.269DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (22 grants)OA: greenTopics (95)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.269

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (99)

Kazuaki Takahashi ORCID,Timothy Budden ORCID,Ahwan Pandey ORCID,Dinuka Ariyaratne ORCID,Tibor A. Zwimpfer ORCID

Live enrichment

PubMed:37986741 OpenAlex:https://openalex.org/W4388562165

National Institutes of Health

Grant: 5R01CA172404-05

Identifying Prognostic Markers and Therapeutic Targets for Serous Ovarian Cancer

National Institutes of Health

Grant: 5P50CA136393-10

Mayo Clinic Ovarian Cancer SPORE

Swiss National Science Foundation

Grant: 172246

Genetic determinants for treatment response and survival in women with high grade serous ovarian cancer

National Health and Medical Research Council (NHMRC)

Grant: 628903

Australasian Biospecimen Network - Oncology

National Health and Medical Research Council (NHMRC)

Grant: 1092856

Improving outcomes for women with epithelial ovarian cancer

National Health and Medical Research Council (NHMRC)

Grant: 1017834

The Adaptive Immune Response to Epstein-Barr virus.

National Institutes of Health

Grant: 5UL1TR000124-04

UCLA Clinical and Translational Science Institute

UK Research and Innovation

Grant: MC_UU_00004/01

Evaluating new healthcare technologies in cancer

National Health and Medical Research Council (NHMRC)

Grant: 1117044

The Molecular Biology of Human Ovarian Cancer

European Commission

Grant: 742432

Understanding cancer development in BRCA 1/2 mutation carriers for improved Early detection and Risk Control

National Health and Medical Research Council (NHMRC)

Grant: 310670

Australasian Biospecimen Network-Oncology

Canadian Institutes of Health Research

Grant: unidentified

unidentified

National Institutes of Health

Grant: 4R01CA168758-04

Epidemiologic factors and survival by molecular subtypes of ovarian cancer

National Health and Medical Research Council (NHMRC)

Grant: 1111032

Pre-clinical Evaluation of the LSD1 Inhibitor HCI-2509: Defining the Biomarkers of Sensitivity and the Mechanisms of Resistance

NCI NIH HHS

Grant: R01 CA172404

NCATS NIH HHS

Grant: UL1 TR000124

Cancer Research UK

Grant: 15601

NCI NIH HHS

Grant: P30 CA015083

NCI NIH HHS

Grant: R01 CA248288

Cancer Research UK

Grant: 22905

NCI NIH HHS

Grant: P30 CA071789

NCI NIH HHS

Grant: P50 CA136393

greenLicense: cc-by

repositoryhttps://www.medrxiv.org/content/medrxiv/early/2023/11/10/2023.11.09.23298321.full.pdf

GREENhttps://www.medrxiv.org/content/medrxiv/early/2023/11/10/2023.11.09.23298321.full.pdf

repositoryhttps://www.medrxiv.org/content/medrxiv/early/2023/11/10/2023.11.09.23298321.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2023.11.09.23298321

repositoryhttps://doi.org/10.1101/2023.11.09.23298321

Fields of Study

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapyDNA Repair MechanismsMedicine0302 clinical medicine03 medical and health sciences

Keywords

Ovarian cancerOvarian carcinomaSerous fluidGermlineSerous carcinomaBiologyCancer researchOncologyCancerInternal medicineMedicineGeneGeneticsBRCA2 Protein (mesh)Women's Health (rcdc)Clinical sciencesCD8-Positive T-LymphocytesNeoplasm Grading (mesh)Precision Medicine (rcdc)Ubiquitin-Protein Ligases (mesh)Tumor-Infiltrating (mesh)2.1 Biological and endogenous factorsSerous (mesh)LymphocytesPrecision Medicine32 Biomedical and Clinical Sciences (for-2020)Cancer (rcdc)Ovarian NeoplasmsHumans (mesh)TumorBRCA1 ProteinRetinoblastoma Binding Proteins (mesh)1112 Oncology and Carcinogenesis (for)Middle AgedPrognosisGene Expression Regulation, NeoplasticRetinoblastoma Binding ProteinsBRCA1 Protein (mesh)Germ-Line Mutation (mesh)FemaleTumor (mesh)Australian Ovarian Cancer Study GroupCD8-Positive T-Lymphocytes (mesh)Ubiquitin-Protein LigasesOncology and CarcinogenesisImmunologyCystadenocarcinoma610Ovarian Neoplasms (mesh)ArticlePrecision Medicine and ImagingRare Diseases (rcdc)Rare DiseasesCancer GenomicsOvarian Cancer (rcdc)Lymphocytes, Tumor-Infiltrating616Middle Aged (mesh)Biomarkers, Tumor3211 Oncology and carcinogenesis (for-2020)HumansOncology & CarcinogenesisTumor-Infiltrating3204 Immunology (for-2020)Germ-Line MutationAgedBRCA2 ProteinNeoplasticNeoplastic (mesh)Biomedical and Clinical SciencesGenetics (rcdc)Aged (mesh)Human GenomeSerous2.1 Biological and endogenous factors (hrcs-rac)Cancer (hrcs-hc)3202 Clinical sciences (for-2020)Prognosis (mesh)Human Genome (rcdc)Cystadenocarcinoma, SerousOrphan DrugGene Expression RegulationOncology & Carcinogenesis (science-metrix)Female (mesh)Orphan Drug (rcdc)Women's HealthNeoplasm GradingCancer Genomics (rcdc)Biomarkers

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: No poverty